Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Rating of “Reduce” from Analysts

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have received an average rating of “Reduce” from the eight analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $17.25.

SLP has been the subject of a number of recent analyst reports. TD Cowen dropped their price target on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, April 10th. William Blair lowered shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 17th. Wall Street Zen cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings upgraded shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 10th. Finally, Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 target price on the stock. in a research report on Thursday, June 18th.

Simulations Plus Trading Down 0.1%

NASDAQ SLP opened at $18.23 on Friday. The stock has a fifty day simple moving average of $16.77 and a 200-day simple moving average of $15.44. The stock has a market cap of $368.79 million, a PE ratio of 45.57 and a beta of 1.30. Simulations Plus has a twelve month low of $11.09 and a twelve month high of $21.01.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.07. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%. The firm had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million. Research analysts predict that Simulations Plus will post 0.8 EPS for the current year.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 4,177 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total value of $77,023.88. Following the sale, the director owned 3,202,131 shares in the company, valued at approximately $59,047,295.64. The trade was a 0.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.10% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in Simulations Plus during the second quarter worth about $25,000. Quarry LP purchased a new position in shares of Simulations Plus in the third quarter valued at approximately $28,000. GAMMA Investing LLC grew its holdings in shares of Simulations Plus by 26.0% in the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after purchasing an additional 585 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Simulations Plus by 59.3% in the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock valued at $53,000 after purchasing an additional 1,669 shares in the last quarter. Finally, Fifth Third Bancorp purchased a new stake in Simulations Plus during the 1st quarter worth approximately $54,000. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.